Towa Pharmaceutical reportedly maintained its bullish rating and raised its target price to ¥6,300. The report also provides the reasons for maintaining the rating as of 5 October, along with consensus information through the previous day.
On 5 October, Japanese mid-sized brokerage IFIS Japan maintained its bullish (Outperform) rating on Towa Pharmaceutical and raised its target price from ¥5,700 to ¥6,300.
The company said that, as of the previous day, the rating consensus was 4.67, with 4.67 bullish ratings among the 6 forecasts, and that the target price consensus was ¥5,250.
Eiken Chemical, Kyorin Pharmaceutical, Santen Pharmaceutical and BML were cited as related stocks, with attention focused on their future performance.